Hospital Formulary Status No
In-Hospital Cost will be updated
PharmaCare Formulary Status Yes (vial-neb) No (inj)
Special Authority Yes (vial-neb) (See below under Restricted Use Criteria)
Special Access Programme Yes (inj) (See below under Restricted Use Criteria)
PharmaCare Coverage 75mg/ml vial-neb - $44.5188/ml
Outpatient Cost 75mg/ml vial-neb - $44.52-57.38/ml
Therapy of gram negative infections including Pseudomonas, particularly in patients with penicillin and cephalosporin allergy or when there is no alternative susceptible agent.
Nebulized form used in cystic fibrosis patients.
Empiric therapy for febrile neutropenia.
Monitor liver enzymes
Special Authority Status: Yes (75mg/ml vial-neb)
Special Authority Category: Limited Coverage Drugs
Special Authority Criteria: For cyclic treatment of chronic Pseudomonas aeruginosa infections in patients with:
Special Authority Approval Period: Indefinite
Special Authority Practitioner Exemptions: None
Special Authority Special Notes:
Special Access Programme (SAP) Status: Yes (inj)
SAP is administered by Health Canada and allows the purchase of drugs unavailable in Canada – please consult with clinical pharmacist if drug is required
Neutropenia (IV)
Thrombocytopenia (IV)
Increase in liver enzymes (IV)
Pulmonary infiltrate with eosinophilia (PIE) syndrome (IV)
CNS toxicity (IV)
Allergic reaction (IV, IM and INH)
Serum sickness (IV, IM and INH)
Rash (IV, IM and INH)
Other
Ceftazidime
No cross-reactivity between penicillin and aztreonam
Antimicrobial class: Monobactam
Pregnancy category: B
Average serum half life: 2.0 hr
Urine penetration: Therapeutic
Lung penetration: Therapeutic
Biliary penetration: Moderate